髂静脉支架植入术后药物治疗策略研究进展

doi:10.3785/j.issn.1008-9292.2020.02.15

浙江大学学报（医学版）

2020, Vol. 49

Issue (1): 131-136 DOI: 10.3785/j.issn.1008-9292.2020.02.15

综述

髂静脉支架植入术后药物治疗策略研究进展

钟文¹(

),楼燕¹,邱宸阳²,李栋林^2,*(

),张鸿坤^2,*(

)

1. 浙江大学医学院附属第一医院药学部, 浙江杭州 310003
2. 浙江大学医学院附属第一医院血管外科, 浙江杭州 310003

Antithrombotic therapy after iliac vein stenting

ZHONG Wen¹(

),LOU Yan¹,QIU Chenyang²,LI Donglin^2,*(

),ZHANG Hongkun^2,*(

)

1. Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2. Department of Vascular Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

全文: PDF(988 KB)

HTML( 12 )

摘要：

近年来支架植入治疗髂静脉狭窄或压迫已有普及趋势，但支架治疗术后抗凝血药和抗血小板药的选择尚无共识。针对非血栓性、急性血栓性和慢性血栓性髂静脉狭窄或压迫这三种不同情况，患者术后用药方案和预后也不尽相同。非血栓性患者无论采用何种抗凝、抗血小板策略，支架通畅率均较满意；急性血栓性患者以抗凝为基础，联用抗血小板药能否额外获益有待进一步探讨；而慢性血栓性患者在不同用药策略下预后均较差。本文就患者术后不同用药方案作一综述，以期为最佳用药策略提供思路。

关键词： 髂静脉; 支架; 手术后; 抗凝血药; 抗血小板药; 综述

Abstract:

Stenting for iliac vein stenosis or compression has become a common therapeutic approach in recent years. The antithrombotic therapy after the stent deployment, however, reaches no consensus. Medications strategies and patients' prognoses differ in non-thrombotic, acute thrombotic and chronic thrombotic these three circumstances. Non-thrombotic patients usually possess satisfactory stent patency whatever antithrombotic therapy is used. Anticoagulant is the basic medication for acute thrombotic patients, benefits from additional antiplatelet drug remains to be clarified. In terms of chronic thrombotic patients, their prognoses are unsatisfactory under all antithrombotic therapies. In this review, we outlined the recent progress of antithrombotic therapy after iliac vein stenting, aiming to provide feasible medication plans for each circumstance.

Key words: Iliac vein Stents Postoperative Anticoagulants Antiplatelet drug Review

收稿日期: 2019-10-15 出版日期: 2020-06-08

CLC:

R654.3

基金资助: 浙江省科技计划(2019C03013)

通讯作者: 李栋林,张鸿坤 E-mail: 6517115@zju.edu.cn;lidonglin@zju.edu.cn;1198050@zju.edu.cn

作者简介: 钟文(1992-), 女, 硕士研究生, 药师, 主要从事药物的临床与基础研究; E-mail:6517115@zju.edu.cn; https://orcid.org/0000-0001-5723-0067

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	钟文
	楼燕
	邱宸阳
	李栋林
	张鸿坤

引用本文:

钟文,楼燕,邱宸阳,李栋林,张鸿坤. 髂静脉支架植入术后药物治疗策略研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 131-136.

ZHONG Wen,LOU Yan,QIU Chenyang,LI Donglin,ZHANG Hongkun. Antithrombotic therapy after iliac vein stenting. J Zhejiang Univ (Med Sci), 2020, 49(1): 131-136.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.02.15 或 http://www.zjujournals.com/med/CN/Y2020/V49/I1/131

1	SCHLEIMER K , BARBATI M E , GROMMES J et al. Update on diagnosis and treatment strategies in patients with post-thrombotic syndrome due to chronic venous obstruction and role of endovenous recanalization[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (4): 592- 600 doi: 10.1016/j.jvsv.2019.01.062
2	LIU G , QIN J , CUI C et al. Comparison of direct iliofemoral stenting following angiojet rheolytic thrombectomy vs staged stenting after angiojet rheolytic thrombectomy plus catheter-directed thrombolysis in patients with acute deep vein thrombosis[J]. J Endovasc Ther, 2018, 25 (1): 133- 139 doi: 10.1177/1526602817714570
3	MURPHY E H , JOHNS B , VARNEY E et al. Deep venous thrombosis associated with caval extension of iliac stents[J]. J Vasc Surg Venous Lymphat Disord, 2017, 5 (1): 8- 17 doi: 10.1016/j.jvsv.2016.09.002
4	JAYARAJ A , BUCK W , KNIGHT A et al. Impact of degree of stenosis in May-Thurner syndrome on iliac vein stenting[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (2): 195- 202 doi: 10.1016/j.jvsv.2018.10.001
5	CHAIT J , ALSHEEKH A , AURSHINA A et al. Effect of venous access site on postintervention stent thrombosis for nonthrombotic iliac vein stenting[J]. J Vasc Surg Venous Lymphat Disord, 2020, 8 (1): 84- 88 doi: 10.1016/j.jvsv.2019.03.014
6	YANG L , LIU J , CAI H et al. The clinical outcome of a one-stop procedure for patients with iliac vein compression combined with varicose veins[J]. J Vasc Surg Venous Lymphat Disord, 2018, 6 (6): 696- 701 doi: 10.1016/j.jvsv.2018.06.012
7	LE T B , LEE T K , PARK K M et al. Contralateral deep vein thrombosis after iliac vein stent placement in patients with may-thurner syndrome[J]. J Vasc Interv Radiol, 2018, 29 (6): 774- 780 doi: 10.1016/j.jvir.2018.01.771
8	AURSHINA A , CHAIT J , KIBRIK P et al. Efficacy of balloon venoplasty alone in the correction of nonthrombotic iliac vein lesions[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (5): 665- 669 doi: 10.1016/j.jvsv.2019.03.004
9	RAZAVI M K , JAFF M R , MILLER L E . Safety and effectiveness of stent placement for iliofemoral venous outflow obstruction:systematic review and meta-analysis[J]. Circ Cardiovasc Interv, 2015, 8 (10): e002772 doi: 10.1161/CIRCINTERVENTIONS.115.002772
10	VAN VUUREN T , DOGANCI S , WITTENS C . Patency rates and clinical outcomes in a cohort of 200 patients treated with a dedicated venous stent[J]. J Vasc Surg Venous Lymphat Disord, 2018, 6 (3): 321- 329 doi: 10.1016/j.jvsv.2017.09.013
11	ZHANG X , JING Y , SANG H et al. Long-term follow-up of the stenting across the iliocaval confluence in patients with iliac venous lesions[J]. J Thromb Thrombolysis, 2019, 47 (1): 134- 139 doi: 10.1007/s11239-018-1757-4
12	VAN VUUREN T , DE WOLF M , ARNOLDUSSEN C et al. Editor's Choice-Reconstruction of the femoro-ilio-caval outflow by percutaneous and hybrid interventions in symptomatic deep venous obstruction[J]. Eur J Vasc Endovasc Surg, 2017, 54 (4): 495- 503 doi: 10.1016/j.ejvs.2017.06.023
13	ATTARAN R R , OZDEMIR D , LIN I H et al. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting:Factors associated with stent occlusion[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (4): 527- 534 doi: 10.1016/j.jvsv.2019.01.058
14	GAGNE P J , GAGNE N , KUCHER T et al. Long-term clinical outcomes and technical factors with the Wallstent for treatment of chronic iliofemoral venous obstruction[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (1): 45- 55 doi: 10.1016/j.jvsv.2018.07.016
15	KIBRIK P , EISENBERG J , ALSHEEKH A et al. Safety and efficacy of stenting nonthrombotic iliac vein lesions in octogenarians and nonagenarians in an office setting[J]. Vascular, 2018, 26 (1): 70- 74 doi: 10.1177/1708538117721624
16	ABDUL-HAQQ R , NOVAK Z , PEARCE B J et al. Routine extended follow-up surveillance of iliac vein stents for iliocaval venous obstruction may not be warranted[J]. J Vasc Surg Venous Lymphat Disord, 2017, 5 (4): 500- 505 doi: 10.1016/j.jvsv.2017.01.018
17	SEBASTIAN T , HAKKI L O , SPIRK D et al. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis[J]. Thromb Res, 2018, 172:86- 93 doi: 10.1016/j.thromres.2018.10.027
18	MING Z B , LI W D , YUAN R F et al. Effectiveness of catheter directed thrombolysis and stent implantation on iliofemoral vein thrombosis caused by iliac vein compression[J]. J Thromb Thrombolysis, 2017, 44 (2): 254- 260 doi: 10.1007/s11239-017-1515-z
19	YU H , DU X , LI W et al. The midterm effect of iliac vein stenting following catheter-directed thrombolysis for the treatment of deep vein thrombosis[J]. Ann Vasc Surg, 2018, 50:1- 7 doi: 10.1016/j.avsg.2018.01.001
20	JIANG C , ZHAO Y , WANG X et al. Midterm outcome of pharmacomechanical catheter-directed thrombolysis combined with stenting for treatment of iliac vein compression syndrome with acute iliofemoral deep venous thrombosis[J]. J Vasc Surg Venous Lymphat Disord, 2020, 8 (1): 24- 30 doi: 10.1016/j.jvsv.2019.03.020
21	CASANEGRA A I , MCBANE R D , BJARNASON H . Intervention radiology for venous thrombosis:early thrombus removal using invasive methods[J]. Br J Haematol, 2017, 177 (2): 173- 184 doi: 10.1111/bjh.14581
22	SIMES J , BECATTINI C , AGNELLI G et al. Aspirin for the prevention of recurrent venous thromboembolism:the INSPIRE collaboration[J]. Circulation, 2014, 130 (13): 1062- 1071 doi: 10.1161/CIRCULATIONAHA.114.008828
23	BECATTINI C , AGNELLI G , SCHENONE A et al. Aspirin for preventing the recurrence of venous thromboembolism[J]. N Engl J Med, 2012, 366 (21): 1959- 1967 doi: 10.1056/NEJMoa1114238
24	BRIGHTON T A , EIKELBOOM J W , MANN K et al. Low-dose aspirin for preventing recurrent venous thromboembolism[J]. N Engl J Med, 2012, 367 (21): 1979- 1987 doi: 10.1056/NEJMoa1210384
25	KEARON C , AKL E A , ORNELAS J et al. Antithrombotic therapy for VTE disease:CHEST guideline and expert panel report[J]. Chest, 2016, 149 (2): 315- 352 doi: 10.1016/j.chest.2015.11.026
26	TAHA M A , BUSUTTIL A , BOOTUN R et al. A systematic review on the use of deep venous stenting for acute venous thrombosis of the lower limb[J]. Phlebology, 2019, 34 (2): 115- 127 doi: 10.1177/0268355518772760
27	MILINIS K , THAPAR A , SHALHOUB J et al. Antithrombotic therapy following venous stenting:international delphi consensus[J]. Eur J Vasc Endovasc Surg, 2018, 55 (4): 537- 544 doi: 10.1016/j.ejvs.2018.01.007
28	HAGE A N , SRINIVASA R N , ABRAMOWITZ S D et al. Endovascular iliocaval stent reconstruction for iliocaval thrombosis:a multi-institutional international practice pattern survey[J]. Ann Vasc Surg, 2018, 49:64- 74 doi: 10.1016/j.avsg.2018.01.076
29	ASCHER E , CHAIT J , PAVALONIS A et al. Fast-track thrombolysis protocol:A single-session approach for acute iliofemoral deep venous thrombosis[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (6): 773- 780 doi: 10.1016/j.jvsv.2019.06.018
30	GURBEL P A , FOX K , TANTRY U S et al. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease[J]. Circulation, 2019, 139 (18): 2170- 2185 doi: 10.1161/circulationaha.118.033580
31	KHAIRY S A , NEVES R J , HARTUNG O et al. Factors associated with contralateral deep venous thrombosis after iliocaval venous stenting[J]. Eur J Vasc Endovasc Surg, 2017, 54 (6): 745- 751 doi: 10.1016/j.ejvs.2017.07.011
32	AVGERINOS E D , SAADEDDIN Z , ABOU ALI A N et al. Outcomes and predictors of failure of iliac vein stenting after catheter-directed thrombolysis for acute iliofemoral thrombosis[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (2): 153- 161 doi: 10.1016/j.jvsv.2018.08.014
33	ENDO M , JAHANGIRI Y , HORIKAWA M et al. Antiplatelet therapy is associated with stent patency after iliocaval venous stenting[J]. Cardiovasc Intervent Radiol, 2018, 41 (11): 1691- 1698 doi: 10.1007/s00270-018-2062-5
34	YIN M , SHI H , YE K et al. Clinical assessment of endovascular stenting compared with compression therapy alone in post-thrombotic patients with iliofemoral obstruction[J]. Eur J Vasc Endovasc Surg, 2015, 50 (1): 101- 107 doi: 10.1016/j.ejvs.2015.03.029
35	RUIHUA W , XIN W , GUANG L et al. Technique and clinical outcomes of combined stent placement for postthrombotic chronic total occlusions of the iliofemoral veins[J]. J Vasc Interv Radiol, 2017, 28 (3): 373- 379 doi: 10.1016/j.jvir.2016.11.003
36	YE K , SHI H , YIN M et al. Treatment of femoral vein obstruction concomitant with iliofemoral stenting in patients with severe post-thrombotic syndrome[J]. Eur J Vasc Endovasc Surg, 2018, 55 (2): 222- 228 doi: 10.1016/j.ejvs.2017.11.029
37	MCDEVITT J L , SRINIVASA R N , HAGE A N et al. Lower extremity endovenous reconstruction for symptomatic occlusive disease in pediatric patients:techniques, clinical outcomes, and long-term stent patencies[J]. Pediatr Radiol, 2019, 49 (6): 808- 818 doi: 10.1007/s00247-019-04357-w
38	CHICK J , SRINIVASA R N , COOPER K J et al. Endovascular iliocaval reconstruction for chronic iliocaval thrombosis:the data, where we are, and how it is done[J]. Tech Vasc Interv Radiol, 2018, 21 (2): 92- 104 doi: 10.1053/j.tvir.2018.03.005
39	ABOUBAKR A , CHAIT J , LURIE J et al. Secondary interventions after iliac vein stenting for chronic proximal venous outflow obstruction[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (5): 670- 676 doi: 10.1016/j.jvsv.2019.02.016
40	MENEZ C , RODIERE M , GHELFI J et al. Endovascular treatment of post-thrombotic venous ilio-femoral occlusions:prognostic value of venous lesions caudal to the common femoral vein[J]. Cardiovasc Intervent Radiol, 2019, 42 (8): 1117- 1127 doi: 10.1007/s00270-019-02214-9
41	IGNATYEV I M , POKROVSKY A , GRADUSOV E . Long-term results of endovascular treatment of chronic iliofemoral venous obstructive lesions[J]. Vasc Endovascular Surg, 2019, 53 (5): 373- 378 doi: 10.1177/1538574419839256

[1]	朱慧琦,应可净. 组织因子与肿瘤患者静脉血栓栓塞[J]. 浙江大学学报（医学版）, 2020, 49(6): 772-778.
[2]	林翠翠,陈正云,王春艳,席咏梅. 基于脂质组学的子宫内膜异位症生物标志物研究进展[J]. 浙江大学学报（医学版）, 2020, 49(6): 779-784.
[3]	李梦瑶,刘盼,柯越海,张雪. 放射性肺损伤中巨噬细胞作用机制的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(5): 623-628.
[4]	韩雪,蒋国军,石巧娟. 降血糖药对内皮祖细胞作用的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(5): 629-636.
[5]	段润平,许叶圣,郑利斌,姚玉峰. 病毒感染性眼病病原学诊断的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(5): 644-650.
[6]	吴唯,徐键. 正五聚蛋白3在多囊卵巢综合征中的作用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(5): 637-643.
[7]	徐清霖,楼国东,王甜甜,张力三. 发作性睡病的药物治疗进展[J]. 浙江大学学报（医学版）, 2020, 49(4): 419-424.
[8]	蒋沛然,王志萍. 模式生物神经轴突再生的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(4): 500-507.
[9]	陈峻逸,杨翔,方学贤,王福俤,闵军霞. 铁死亡与重大慢性疾病[J]. 浙江大学学报（医学版）, 2020, 49(1): 44-57.
[10]	俞卿, 熊秀芳, 孙毅. 靶向Cullin-RING E3泛素连接酶的抗肿瘤策略及相关药物研发进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 1-19.
[11]	段玲艳,尹香菊,孟红恩,方学贤,闵军霞,王福俤. 铁稳态代谢表观遗传调控机制的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 58-70.
[12]	李艾,张添源,高建青. 间充质干细胞的肿瘤归巢特性及其肿瘤靶向治疗应用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 20-34.
[13]	黄耀凭,杨凤,周天华,谢珊珊. Hippo信号通路及其在消化系统肿瘤中的作用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 35-43.
[14]	徐亦鸣,应可净. 中性粒细胞胞外诱捕网与肿瘤相关研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 107-112.
[15]	刘晓晓,郭莉琼,梁成. 抗N-甲基-D-天冬氨酸受体脑炎患者脑电图特点的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 118-123.

Viewed

Full text

Abstract

Cited

Shared

Discussed